import ArticleLayout from './ArticleLayout';

const HeroVisual = () => (
  <svg viewBox="0 0 520 400" className="w-full max-w-[460px]" aria-hidden="true">
    <defs>
      <linearGradient id="aiJudg" x1="0" y1="0" x2="1" y2="0">
        <stop offset="0" stopColor="#f59e0b" stopOpacity="0.7" />
        <stop offset="1" stopColor="#f59e0b" stopOpacity="1" />
      </linearGradient>
    </defs>

    {/* Eyebrow */}
    <text x="20" y="24" fill="rgba(255,255,255,0.55)" fontSize="11" fontFamily="Lexend, sans-serif" letterSpacing="2.5" fontWeight="500">
      ONE CONSULTANT WEEK · TIME ALLOCATION
    </text>
    <line x1="20" y1="34" x2="60" y2="34" stroke="#2e8bc0" strokeWidth="1.5" />

    {/* Grid guide */}
    <g stroke="rgba(255,255,255,0.08)" strokeDasharray="2 4">
      <line x1="20" y1="70" x2="380" y2="70" />
      <line x1="20" y1="300" x2="380" y2="300" />
    </g>

    {/* Row 1: PRE-AI */}
    <text x="20" y="88" fill="rgba(255,255,255,0.72)" fontSize="12" fontFamily="Lexend, sans-serif" fontWeight="500" letterSpacing="2.5">PRE-AI</text>
    <g transform="translate(20, 100)">
      <rect x="0" y="0" width="270" height="50" fill="rgba(255,255,255,0.10)" stroke="rgba(255,255,255,0.30)" strokeWidth="1" />
      <rect x="270" y="0" width="90" height="50" fill="url(#aiJudg)" />
      <text x="135" y="31" fill="rgba(255,255,255,0.72)" fontSize="11" fontFamily="Lexend, sans-serif" fontWeight="500" letterSpacing="2" textAnchor="middle">ASSEMBLY · 75%</text>
      <text x="315" y="31" fill="#fff" fontSize="10" fontFamily="Lexend, sans-serif" fontWeight="600" letterSpacing="1.5" textAnchor="middle">25%</text>
    </g>

    {/* Row 2: AI-AUGMENTED */}
    <text x="20" y="225" fill="#7fb7d9" fontSize="12" fontFamily="Lexend, sans-serif" fontWeight="600" letterSpacing="2.5">AI-AUGMENTED</text>
    <g transform="translate(20, 237)">
      <rect x="0" y="0" width="72" height="50" fill="rgba(255,255,255,0.10)" stroke="rgba(255,255,255,0.30)" strokeWidth="1" />
      <rect x="72" y="0" width="288" height="50" fill="url(#aiJudg)" />
      <text x="36" y="31" fill="rgba(255,255,255,0.7)" fontSize="10" fontFamily="Lexend, sans-serif" fontWeight="500" letterSpacing="1.5" textAnchor="middle">20%</text>
      <text x="216" y="31" fill="#fff" fontSize="12" fontFamily="Lexend, sans-serif" fontWeight="600" letterSpacing="2" textAnchor="middle">JUDGMENT · 80%</text>
    </g>

    {/* Dotted guide showing judgment edge shifting left */}
    <path d="M 290 150 Q 180 193 92 237" fill="none" stroke="rgba(245,158,11,0.55)" strokeWidth="1.3" strokeDasharray="3 4" />

    {/* 3× JUDGMENT callout */}
    <g transform="translate(395, 180)">
      <line x1="0" y1="-20" x2="14" y2="-20" stroke="#f59e0b" strokeWidth="1.3" />
      <line x1="14" y1="-20" x2="14" y2="38" stroke="#f59e0b" strokeWidth="1.3" />
      <line x1="0" y1="38" x2="14" y2="38" stroke="#f59e0b" strokeWidth="1.3" />
      <text x="24" y="10" fill="#f59e0b" fontSize="26" fontWeight="700" fontFamily="Lexend, sans-serif">3×</text>
      <text x="24" y="28" fill="rgba(245,158,11,0.75)" fontSize="10" fontFamily="Lexend, sans-serif" letterSpacing="2.5">JUDGMENT</text>
    </g>
  </svg>
);

const AiAdvisory = () => (
  <ArticleLayout
    category="AI & Advisory"
    title="The 3x Deliverable Model: How AI Is Reshaping Biotech Consulting"
    subtitle="Why the future of advisory isn't cheaper consulting. It's fundamentally better outcomes, delivered through AI-augmented intelligence."
    readTime="9 min read"
    publishDate="April 2026"
    isoDate="2026-04-14"
    slug="ai-reshaping-biotech-consulting"
    heroGradient="from-primary via-primary/80 to-secondary/90"
    heroVisual={<HeroVisual />}
    ogImage="/articles/ai-advisory.jpg"
  >
    <p className="lede">
      The biotech consulting industry is at an inflection point. Not because AI is going to replace consultants,
      but because AI is changing what a single consultant can credibly deliver in a week. The firms that win the
      next decade are not the cheapest ones. They are the ones who use AI to compress the analytical distance
      between a client&apos;s question and a defensible answer.
    </p>

    <div className="stat-grid">
      <div className="stat-card">
        <span className="num">3x</span>
        <span className="label">Deliverable depth per engagement week</span>
      </div>
      <div className="stat-card">
        <span className="num">$60–110B</span>
        <span className="label">Annual AI value in pharma (McKinsey, 2023)</span>
      </div>
      <div className="stat-card">
        <span className="num">30%+</span>
        <span className="label">Productivity gains in knowledge work (Bain)</span>
      </div>
    </div>

    <h2>The consulting model, rebuilt</h2>

    <p>
      McKinsey&apos;s 2023 analysis estimated that generative AI could add <strong>$60 billion to $110 billion
      annually</strong> to pharma and medical products alone, with applications spanning drug discovery, trial
      design, commercial forecasting, and market access. A curious thing happens when the same tools are applied to
      the advisory layer that sits on top of pharma operations: the economics of consulting itself start to shift.
    </p>

    <p>
      The traditional consulting engagement followed a predictable pattern. A senior partner scopes the problem.
      A team of 3 to 5 analysts spends 4 to 6 weeks gathering, cleaning, and synthesizing data. A mid-level
      engagement manager shapes the findings into a deck. The partner presents. The client pays for all of it.
    </p>

    <p>
      AI does not eliminate any of those roles. But it radically reshapes what the analyst layer produces. In our
      own advisory practice, we&apos;ve tracked deliverable output across comparable engagements before and after
      AI-augmented workflows became standard:
    </p>

    <div className="table-wrap">
    <table className="data-table">
      <thead>
        <tr>
          <th>Deliverable Type</th>
          <th>Pre-AI (hours)</th>
          <th>AI augmented (hours)</th>
          <th>Quality signal</th>
        </tr>
      </thead>
      <tbody>
        <tr><td>Competitive landscape (20 companies)</td><td>80 to 120</td><td>20 to 30</td><td>Broader coverage</td></tr>
        <tr><td>Clinical trial design benchmark</td><td>~60</td><td>~15</td><td>More comparators</td></tr>
        <tr><td>Scientific literature synthesis</td><td>~40</td><td>~8</td><td>Parity to mild gain</td></tr>
        <tr><td>Market sizing (top-down)</td><td>~30</td><td>~10</td><td>Parity</td></tr>
        <tr><td>Regulatory precedent review</td><td>~50</td><td>~12</td><td>Deeper historical reach</td></tr>
      </tbody>
    </table>
    </div>

    <div className="callout">
      <span className="callout-label">The 3x Framing</span>
      <p className="mb-0">
        We call it the 3x deliverable model because across a typical four week engagement, AI-augmented teams
        produce roughly three times the analytical depth per consultant week. Not by working harder, but by
        automating the assembly layer and freeing senior time for judgment.
      </p>
    </div>

    <h2>What AI is genuinely good at (and what it is not)</h2>

    <p>
      Being specific matters here. In biotech advisory work, AI delivers outsized value in three zones and
      remains a liability in a fourth:
    </p>

    <h3>Where AI compounds analyst output</h3>
    <ul>
      <li>
        <strong>Unstructured data synthesis.</strong> Scientific literature, SEC filings, conference presentations,
        FDA briefing documents. A modern large language model can process hundreds of thousands of tokens of primary
        source material and produce a structured synthesis in minutes, work that would have taken an associate a
        full week.
      </li>
      <li>
        <strong>Multi source reconciliation.</strong> ClinicalTrials.gov, the NMPA registry, EudraCT, investor
        presentations, scientific abstracts. Cross-referencing and deduplicating these sources used to be the
        bulk of associate time. AI tooling brings this from days to hours with higher fidelity.
      </li>
      <li>
        <strong>First draft artifact generation.</strong> Slide outlines, executive summaries, data tables,
        sensitivity analysis structures. Not a finished product, but a starting point that eliminates the blank
        page problem.
      </li>
    </ul>

    <h3>Where AI is still a liability</h3>
    <ul>
      <li>
        <strong>Judgment under ambiguity.</strong> Whether a Phase IIa readout is compelling in the context of
        a specific competitive landscape is not a pattern matching problem. It is a judgment call informed by
        tacit knowledge. AI systems remain confidently wrong about exactly this category of question.
      </li>
    </ul>

    <div className="callout">
      <span className="callout-label">How Echo ships this every month</span>
      <p className="mb-0">
        Unstructured synthesis, multi-source reconciliation, and first-draft artifact generation are exactly what
        Echo&apos;s retainer clients receive continuously: a live runway model, a monthly board deck, an
        always-on investor pipeline, and a KPI dashboard. The AI produces the assembly. A senior advisor owns
        the judgment and the client relationship.
      </p>
    </div>

    <blockquote>
      The value of a senior biotech advisor has gone up, not down, in the age of AI. The commodity work has
      collapsed in price. The judgment work has become more visible, and more valuable, as a result.
    </blockquote>

    <h2>Where the value accrues</h2>

    <p>
      An interesting question: if AI compresses analyst hours by 60 to 75%, does consulting get cheaper? In the
      short term, for commoditized work, yes. Bain &amp; Company&apos;s research on generative AI in professional
      services points to 30%+ productivity gains in knowledge work intensive service industries, with the fastest
      gains in research heavy verticals. For biotech advisory specifically, we see three distinct market segments
      evolving:
    </p>

    <div className="bar-chart">
      <div className="bar-row">
        <div className="bar-label"><span className="bar-name">Commoditized research (market sizing, basic landscaping)</span><span className="bar-value">~45% price decline</span></div>
        <div className="bar-track"><div className="bar-fill" style={{ width: '45%' }} /></div>
      </div>
      <div className="bar-row">
        <div className="bar-label"><span className="bar-name">Strategic advisory (complex tradeoffs, deal support)</span><span className="bar-value">Stable pricing</span></div>
        <div className="bar-track"><div className="bar-fill" style={{ width: '10%' }} /></div>
      </div>
      <div className="bar-row">
        <div className="bar-label"><span className="bar-name">Cross-border / specialized judgment</span><span className="bar-value">Premium growing</span></div>
        <div className="bar-track"><div className="bar-fill" style={{ width: '25%' }} /></div>
      </div>
    </div>

    <p>
      The lesson: AI is deflating the middle and expanding the edges. Purely analytical work is becoming cheaper;
      advisory work that requires genuine judgment, relationships, and cross-border operational knowledge is
      becoming <em>more</em> valuable, because the comparative advantage of human advisors is now more concentrated
      in exactly those capabilities.
    </p>

    <h2>What this looks like in practice</h2>

    <p>
      Consider a real engagement shape we see often: a Phase II biotech preparing for a Series C raise wants to
      understand how five specific competitor programs will read out over the next 18 months. In the pre-AI
      model, a team of two associates would spend three weeks assembling this analysis from scratch. In the
      AI-augmented model:
    </p>

    <ol>
      <li>
        A single analyst uses AI tooling to pull, structure, and cross-reference every public disclosure about
        those five programs: clinical trial registrations, scientific presentations, SEC filings, patent filings,
        investor calls, in 2 to 3 days.
      </li>
      <li>
        A senior advisor spends a day inspecting the synthesis, identifying the analytical gaps AI missed (typically
        tacit industry knowledge about specific investigators, sites, or historical precedents), and commissioning
        targeted primary research to fill them.
      </li>
      <li>
        The client receives in week two what used to take four weeks, and the last two weeks are spent on strategic
        interpretation rather than data collection.
      </li>
    </ol>

    <p>
      The client pays slightly less, but gets substantially more. The firm earns a better margin because analyst
      time on commoditized assembly has collapsed. And the senior advisor spends their time doing the thing their
      experience actually warrants: making calls on ambiguous situations.
    </p>

    <h2>What biotech clients should ask their advisors</h2>

    <p>
      If you are evaluating a strategic advisor in 2026, the right questions have changed. Instead of asking
      about team size and industry credentials, ask:
    </p>

    <ul>
      <li>&quot;What percentage of your analyst work is AI augmented, and how do you verify the output?&quot;</li>
      <li>&quot;Can I see a sample of a deliverable where AI did 70% of the assembly?&quot;</li>
      <li>&quot;How has your pricing structure changed in the last 24 months, and why?&quot;</li>
      <li>&quot;Where do you explicitly <em>not</em> use AI, and what is your reasoning?&quot;</li>
    </ul>

    <p>
      Firms that can answer these questions crisply have thought about how AI actually fits into advisory work.
      Firms that cannot have usually done one of two things: resisted AI entirely (and will be uncompetitive on
      price) or adopted it uncritically (and will deliver confidently wrong work at speed).
    </p>

    <h2>How Echo operates under the 3x model</h2>

    <p>
      Echo International Medica is built as a working example of the model this article describes. Our flagship
      product is a <strong>Fractional AI CFO retainer for biotech</strong>, a monthly subscription that replaces
      the feast-or-famine cycle of project-based finance and fundraising consulting with a continuous, AI-augmented
      delivery:
    </p>

    <ul>
      <li>
        <strong>Live runway and scenario model</strong>, refreshed as accounting, headcount, and clinical milestones
        change. The CEO does not wait for a quarterly rebuild to see the effect of a trial slip.
      </li>
      <li>
        <strong>Monthly board deck and investor update</strong>, drafted from the live model and finalized by a
        senior advisor. One consistent story to the board, the lead, and new investors.
      </li>
      <li>
        <strong>Always-on investor pipeline</strong> with AI thesis-fit scoring across hundreds of biotech investors
        and warm-intro mapping. When the data reads out, the list is already prioritized.
      </li>
      <li>
        <strong>KPI dashboard</strong> tracking burn, cash-to-milestone coverage, and pipeline velocity, so the
        board meeting opens with the same numbers everyone already trusts.
      </li>
    </ul>

    <div className="callout">
      <span className="callout-label">Why retainer, not hours</span>
      <p className="mb-0">
        Biotech finance is not a discrete project. Cash runway, investor relationships, and board reporting are
        continuous functions. We charge a flat monthly retainer because that aligns incentives with what clients
        actually need: always-on discipline, not another deck delivered three weeks after it would have been
        useful. AI does the analytical work. A senior advisor owns the judgment calls and the client relationship.
        One senior FTE can supervise 8 to 12 clients without quality loss, which is where the 3x economics live.
      </p>
    </div>

    <h2>The bottom line</h2>

    <p>
      The 3x deliverable model is not a productivity slogan. It is a structural description of how value is being
      redistributed in the consulting industry. Commoditized research is collapsing in price. Strategic judgment
      is appreciating. The consulting firms that thrive will be the ones who see both trends clearly and build
      their staffing, pricing, and delivery models accordingly.
    </p>

    <p>
      For biotech clients, the implication is simple: expect more for less on commoditized work, and pay
      premium rates for advisors who can genuinely solve the harder problems. The middle ground, generalist
      firms charging premium rates for commoditized output, is the category that gets hollowed out.
    </p>

    <div className="sources">
      <h4>Sources &amp; References</h4>
      <ol>
        <li>McKinsey &amp; Company. &quot;The economic potential of generative AI: The next productivity frontier,&quot; June 2023. <a href="https://www.mckinsey.com/capabilities/mckinsey-digital/our-insights/the-economic-potential-of-generative-ai-the-next-productivity-frontier" target="_blank" rel="noopener">mckinsey.com</a>.</li>
        <li>McKinsey &amp; Company. &quot;Generative AI in the pharmaceutical industry: Moving from hype to reality,&quot; 2024.</li>
        <li>Bain &amp; Company. Generative AI research and practitioner briefs on professional services productivity, 2023 to 2024.</li>
        <li>BCG. Reports on generative AI applications in pharma R&amp;D and operations, 2023 to 2024.</li>
        <li>Deloitte. &quot;Measuring the return from pharmaceutical innovation,&quot; annual series.</li>
        <li>Accenture. &quot;Reinventing Life Sciences with Generative AI,&quot; 2024.</li>
        <li>Echo International Medica. Internal engagement productivity benchmarks, 2023 to 2025.</li>
      </ol>
    </div>
  </ArticleLayout>
);

export default AiAdvisory;
